MONOCLONAL ANTIBODY THERAPY FOR HIGH-RISK CORONAVIRUS (COVID 19) PATIENTS WITH MILD TO MODERATE DISEASE PRESENTATIONS

Course overview

CORONAVIRUS DISEASE 2019 (COVID-19), THE ILLNESS CAUSED BY SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2), HAS HAD AN UNPRECEDENTED IMPACT ON THE WORLD’S POPULATION RESULTING IN MORE THAN 2.8 MILLION DEATHS. PREVENTING THE PROGRESSION OF COVID-19 ILLNESS IN PATIENTS WITH MILD TO MODERATE FORMS OF THE DISEASE IS CRUCIAL TO IMPROVING THE GLOBAL BURDEN OF THIS ILLNESS AND THE ASSOCIATED CLINICAL OUTCOMES. A PROMISING APPROACH TO THE ACHIEVEMENT OF THIS GOAL IS THE USE OF NEUTRALIZING MONOCLONAL ANTIBODIES. THIS ACTIVITY HIGHLIGHTS THE USE OF MONOCLONAL ANTIBODY THERAPY BY THE INTERPROFESSIONAL TEAM FOR MILD TO MODERATE COVID-19 ILLNESS PATIENTS IN AN OUTPATIENT/AMBULATORY SETTING WHO ARE AT HIGH RISK OF DEVELOPING SEVERE DISEASE.